Mineralys Therapeutics Inc expected to post a loss of $1.08 a share - Earnings Preview

Mineralys Therapeutics

10/02/2025 14:00

* Mineralys Therapeutics Inc  MLYS.OQ   MLYS.O  is expected
to show no change in quarterly revenue when it reports 
results on February 12 for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Mineralys Therapeutics
Inc is
for a loss of $1.08 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mineralys
Therapeutics Inc is $32.00​, above​ its last closing price
of $9.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.87       -0.83      -1.13     Missed  -35.4
 Jun. 30 2024  -0.70       -0.70      -0.83     Missed  -18.6
 Mar. 31 2024  -0.61       -0.67      -0.70     Missed  -4.8​
 Dec. 31 2023              -0.82      -0.61     Beat    26.1
 ​​Sep.        -0.70       -0.76      -0.57     Beat    25
 30 2023                                                
 Jun. 30 2023  -0.67       -0.72      -0.31     Beat    56.9​
 Mar. 31 2023  -0.88       -0.89      -0.51     Beat    42.7
 Dec. 31 2022  -1.72       -1.72      -1.74     Missed  -1.2
 This summary was machine generated February 10 at 14:00 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)